H Pylori
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 14, 2007; 13(10): 1541-1546
Published online Mar 14, 2007. doi: 10.3748/wjg.v13.i10.1541
Expression of mutant type-p53 products in H pylori-associated chronic gastritis
Masaaki Kodama, Kazunari Murakami, Tadayoshi Okimoto, Ryugo Sato, Koichiro Watanabe, Toshio Fujioka
Masaaki Kodama, Kazunari Murakami, Tadayoshi Okimoto, Ryugo Sato, Koichiro Watanabe, Toshio Fujioka, Department of Gastroenterology, Faculty of Medicine, Oita University, Hasama-machi, Oita, 879-5593, Japan
Author contributions: All authors contributed equally to the work.
Supported by Grants-in-Aid (C-14) from the Ministry of Health, Labor and Welfare, Japan
Correspondence to: Masaaki Kodama, Department of Gastroen-terology, Faculty of Medicine, Oita University, Hasama-machi, Oita, 879-5593, Japan. kodm@med.oita-u.ac.jp
Telephone: +81-975-86-6193 Fax: +81-975-86-6194
Received: December 18, 2006
Revised: January 20, 2007
Accepted: February 25, 2007
Published online: March 14, 2007
Abstract

AIM: To investigate the mutation of p53 immuno-histochemically in non-tumorous gastric mucosa with H pylori infection before and after H pylori eradication therapy.

METHODS: 53 subjects (36 male, 17 female, mean age ± SEM, 57.1 ± 12.1) undergoing endoscopic examination were included in this study. 42 of 53 patients were H pylori-positive, and 11 were H pylori-negative. All H pylori-positive patients had successful eradication therapy. Biopsy specimens were taken from five points of the stomach, as recommended by the updated Sydney system. Immunohistochemical studies were performed by using primary antibodies against p53 (DO-7 and PAb240).

RESULTS: p53 (DO-7 and PAb240) immunoreactivity was shown in the neck region of the gastric pits, however, quite a few cells were found to be immunopositive for p53 (PAb240) in the H pylori-infected gastric mucosa. The proportion of patients immunopositive for p53 (PAb240) was significantly reduced 6 mo after eradication [28/42 (66.7%) to 6/42 (14.3%)] (P < 0.05), while the biopsies taken from H pylori-negative patients showed no immunoreactivity for p53 (PAb240). p53 (PAb240)-positive patients were divided into two groups by the number of positive cells detected: one with more than six positive cells per 10 gastric pits (group A, n = 12), and the other with less than five positive cells per 10 gastric pits (group B, n = 30). Atrophy scores in group A were significant higher than those in group B at the greater curvature of the antrum (group A: 2.00 ± 0.14 vs group B: 1.40 ± 0.15, P = 0.012), the lesser curvature of the corpus (group A: 2.00 ± 0.21 vs group B: 1.07 ± 0.23, P = 0.017), and the greater curvature of the corpus (group A: 1.20 ± 0.30 vs group B: 0.47 ± 0.21, P = 0.031). Group A showed significant higher intestinal metaplasia scores than group B only at the lesser curvature of the antrum (group A: 2.10 ± 0.41 vs group B: 1.12 ± 0.29, P = 0.035).

CONCLUSION: H pylori-associated chronic gastritis expressed the mutant-type p53, which was significantly associated with more severe atrophic and metaplastic changes. H pylori eradication led to a significant reduction in the expression of the mutant-type p53. It is considered that H pylori-infected chronic gastritis is associated with a genetic instability that leads to gastric carcinogenesis, and H pylori eradication may prevent gastric cancer.

Keywords: H pylori, H pylori eradication, Atrophic gastritis, Mutant-type p53, Gastric cancer, Updated Sydney system